The Importance of NLRP3 Inflammasome in Heart Failure

Journal of Cardiac Failure

Volumn 21, Issue 7, 2015, Pages 586-593

  Butts, Brittany ^a   Gary, Rebecca A ^a   Dunbar, Sandra B ^a   Butler, Javed ^b  

^a EMORY UNIVERSITY   (United States)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

Heart failure; inflammasome; inflammation

Indexed keywords

CANAKINUMAB; CORTICOSTEROID; CRYOPYRIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INFLAMMASOME; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR ALPHA; AUTACOID; CARRIER PROTEIN; NLRP3 PROTEIN, HUMAN;

CHRONIC INFLAMMATION; DISEASE COURSE; DRUG TARGETING; EPIGENETICS; HEART FAILURE; HUMAN; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; UPPER RESPIRATORY TRACT INFECTION; VASCULAR REMODELING; IMMUNOLOGY; INFLAMMATION;

CARRIER PROTEINS; DISEASE PROGRESSION; HEART FAILURE; HUMANS; INFLAMMASOMES; INFLAMMATION; INFLAMMATION MEDIATORS; NLR FAMILY, PYRIN DOMAIN-CONTAINING 3 PROTEIN;

EID: 84943585944     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2015.04.014     Document Type: Review

References (73)

1. G.D. Eslick, B.V. Thampan, M. Nalos, A.S. McLean, and R. Sluyter Circulating interleukin-18 concentrations and a loss-of-function P2x7 polymorphism in heart failure Int J Cardiol 137 2009 81 83
2. B. van Tassell, A. Varma, F.N. Salloum, A. Das, I.M. Seropian, S. Toldo, and et al. Interleukin-1 trap attenuates cardiac remodeling after experimental acute myocardial infarction in mice J Cardiovasc Pharmacol 22 2010 117 122
3. P.A. Heidenreich, J.G. Trogdon, O.A. Khavjou, J. Butler, K. Dracup, M.D. Ezekowitz, and et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association Circulation 123 2011 933 944
4. C.W. Yancy, M. Jessup, B. Bozkurt, J. Butler, D.E. Casey Jr., M.H. Drazner, and et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 62 2013 e147 e239
5. A. Abbate The heart on fire: inflammasome and cardiomyopathy Exp Physiol 98 2013 385
6. M. Packer The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure J Am Coll Cardiol 20 1992 248 254
7. Y. Seta, K. Shan, B. Bozkurt, H. Oral, and D.L. Mann Basic mechanisms in heart failure: the cytokine hypothesis J Card Fail 2 1996 243 249
8. E.S. Chung, M. Packer, K.H. Lo, A.A. Fasanmade, and J.T. Willerson Randomized, double-blind, placebo-controlled, pilot trial of Infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure. Results of the Anti-TNF Therapy Against Cognestive Heart Failure (ATTACH) Trial Circulation 107 2003 3133 3140
9. U. Hofmann, and S. Frantz How can we cure a heart "in flame"? A translational view on inflammation in heart failure Basic Res Cardiol 108 2013 356 375
10. A.A. El-Menyar Cytokines and myocardial dysfunction: state of the art J Card Fail 14 2008 61 74
11. S. von Haehling, J.C. Schefold, M. Lainscak, W. Doehner, and S.D. Anker Inflammatory biomarkers in heart failure revisited: Much more than innocent bystanders Heart Failure Clin 5 2009 549 560
12. N.A. Bracey, P.L. Beck, D.A. Muruve, S.A. Hirota, J. Guo, H. Jabagi, and et al. The Nlrp3 inflammasome promotes myocardial dysfunction in structural cardiomyopathy through interleukin-1β Exp Physiol 98 2013 462 472
13. E. Mezzaroma, S. Toldoa, D. Farkasb, I.M. Seropiana, B.W.V. Tassellb, F.N. Sallouma, and et al. The inflammasome promotes adverse cardiac remodeling following acute myocardial infarction in the mouse Proc Natl Acad Sci U S A 108 2011 19725 19730
14. M. Kawaguchi, M. Takahashi, T. Hata, Y. Kashima, F. Usui, H. Morimoto, and et al. Inflammasome activation of cardiac fibroblasts is essential for myocardial ischemia/reperfusion injury Circulation 123 2011 594 604
15. H. Nakayama, and K. Otsu Translation of hemodynamic stress to sterile inflammation in the heart Trends Endocrinol Metab 24 2013 546 553
16. I. Tabas, and C.K. Glass Anti-inflammatory therapy in chronic disease: challenges and opportunities Science 336 2013 166 172
17. H. Otani The role of nitric oxide in myocardial repair and remodeling Antioxid Redox Signal 11 2009 1913 1928
18. M. Elahi, S. Asopa, and B. Matata NO-cGMP and TNF-α counter regulatory system in blood: understanding the mechanisms leading to myocardial dysfunction and failure Biochim Biophys Acta 1772 2010 5 14
19. M. Vaduganathan, S.J. Greene, J. Butler, H.N. Sabbah, E. Shantsila, G.Y.H. Lip, and et al. The immunological axis in heart failure: importance of the leukocyte differential Heart Fail Rev 18 2013 835 845
20. J.C. Campos, K.M. Gomes, and J.C. Ferreira Impact of exercise training on redox signaling in cardiovascular diseases Food Chem Toxicol 62 2013 107 119
21. N. Glezeva, and J.A. Baugh Role of inflammation in the pathogenesis of heart failure with preserved ejection fraction and its potential as a therapeutic target Heart Fail Rev 19 2014 681 694
22. K. Schroder, R. Zhou, and J. Tschopp The NLRP3 inflammasome: a sensor for metabolic danger? Science 327 2010 296 300
23. T.D. Kanneganti, M. Lamkanfi, and G. Nunez Intracellular NOD-like receptors in host defense and disease Immunity 27 2007 549 559
24. A. Abbate, M.C. Kontos, J.D. Grizzard, G.G.L. Biondi-Zoccai, B. Van Tassell, R. Robati, and et al. Interleukin-1 blockade with Anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] pilot study) Am J Cardiol 105 2010 1371 1377
25. A. Abbate, B.W. van Tassell, G. Biondi-Zoccai, M.C. Kontos, J.D. Grizzard, D.W. Spillman, and et al. Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) pilot study] Am J Cardiol 111 2013 1394 1400
26. K. Schroder, and J. Tschopp The inflammasome Cell Adhes Commun 140 2010 821 832
27. M. Lamkanfi, and V.M. Dixit Inflammasomes and their roles in health and disease Annu Rev Cell Dev Biol 28 2012 137 161
28. T. Strowig, J. Henao-Mejia, E. Elinav, and R. Flavell Inflammasomes in health and disease Nat Biotechnol 481 2012 278 286
29. F.S. Sutterwala, S. Haasken, and S.L. Cassel Mechanism of NLRP3 inflammasome activation Ann N Y Acad Sci 1319 2014 82 95
30. M. Takahashi NLRP3 inflammasome as a novel player in myocardial infarction Int Heart J 55 2014 101 105
31. K. Nakajima, M. Takeoka, M. Mori, S. Hashimoto, A. Sakurai, H. Nose, and et al. Exercise effects on methylation of ASC gene Int J Sports Med 31 2010 671 675
32. H. Okamura, H. Tsutsui, S.-I. Kashiwamura, T. Yoshimoto, and K. Nakanishi Interleukin-18: a novel cytokine that augments both innate and acquired immunity Adv Immunol 70 1998 281 312
33. P.W. Fedak, S. Verma, R.D. Weisel, and R.-K. Li Cardiac remodeling and failure. From molecules to man (part 1) Cardiovasc Pathol 14 2005 1 11
34. F.G. Bauernfeind, G. Horvath, A. Stutz, E.S. Alnemri, K. MacDonald, D. Speert, and et al. Cutting edge: NF-kB activating pattern recognition and cytokine receptors license NLRP3 inflammasomeactivation by regulating NLRP3 expression J Immunol 183 2009 787e91
35. J. Tschopp, and K. Schroder NLRP3 inflammasome activation: the convergence of multiple signalling pathways on ROS production? Nat Rev Immunol 10 2010 210 215
36. M. Lamkanfi, and V.M. Dixit Mechanisms and functions of inflammasomes Cell 157 2014 1013 1022
37. F. Martinon, A. Mayor, and J. Tschopp The inflammasomes: guardians of the body Annu Rev Immunol 27 2009 229 265
38. N.A. Bracey, B. Gershkovich, J. Chun, A. Vilaysane, H.C. Meijndert, J.R. Wright Jr., and et al. Mitochondrial NLRP3 protein induces reactive oxygen species to promote Smad signaling and fibrosis independent from the inflammasome J Biol Chem 289 2014 19571 19584
39. S. PvWilson, and S.L. Cassel Inflammasome-mediated autoinflammatory disorders Postgrad Med J 122 2010 125 133
40. S. Taniguchi, and J. Sagara Regulatory molecules involved in inflammasome formation with special reference to a key mediator protein, ASC Semin Immunopathol 29 2007 231 238
41. C.A. Dinarello Immunological and inflammatory functions of the interleukin-1 family Annu Rev Immunol 27 2009 519 550
42. C.A. Dinarello A clinical perspective of IL-1β as the gatekeeper of inflammation Eur J Immunol 41 2011 1203 1217
43. B. van Tassell, I.M. Seropian, S. Toldo, E. Mezzaroma, and A. Abbate Interleukin-1β induces a reversible cardiomyopathy in the mouse Inflamm Res 62 2013 637 640
44. B. van Tassell, R.A. Arena, S. Toldo, E. Mezzaroma, T. Azam, I.M. Seropian, and et al. Enhanced interleukin-1 activity contributes to exercise intolerance in patients with systolic heart failure PLoS ONE 7 2012 e33438
45. B.J. Pomerantz, L.L. Reznikov, A.H. Harken, and C.A. Dinarello Inhibition of caspase 1 reduces human myocardial ischemic dysfunction via inhibition of IL-18 and IL-1β Proc Natl Acad Sci U S A 98 2001 2871 2876
46. A. Abbate, B. Van Tassell, I.M. Seropian, S. Toldo, R. Robati, A. Varma, and et al. Interleukin-1b modulation using a genetically engineered antibody prevents adverse cardiac remodelling following acute myocardial infarction in the mouse Eur J Heart Fail 12 2010 319 322
47. C.A. Dinarello, A. Simon, and J. van der Meer Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases Nat Rev Drug Discov 11 2012 633 652
48. Z. Mallat, C. Heymes, A. Corbaz, D. Logeart, S. Alouani, A. Cohen-Solal, and et al. Evidence for altered interleukin 18 (IL)-18 pathway in human heart failure FASEB J 18 2004 1752 1754
49. H2 cytokine imbalance exaggerates the pathophysiology of advanced heart failure J Card Fail 8 2002 21 27
50. N. Ueno, S. Kashiwamura, H. Ueda, H. Okamura, N.M. Tsuji, K. Hosohara, and et al. Role of interleukin 18 in nitric oxide production and pancreatic damage during acute pancreatitis Shock 24 2005 564 570
51. S. Umar, and A. van der Laarse Nitric oxide and nitric oxide synthase isoforms in the normal, hypertrophic and failing heart Mol Cell Biochem 333 2010 191 201
52. M. Hedayat, M.J. Mahmoudi, N.R. Rose, and N. Rezaei Proinflammatory cytokines in heart failure: double-edged swords Heart Fail Rev 15 2010 543 562
53. B. Bozkurt, G. Torre-Amione, M.S. Warren, J. Whitmore, O.Z. Soran, A.M. Feldman, and et al. Results of targeted antitumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure Circulation 103 2001 1044 1047
54. T. Burkard, O. Pfister, H. Rickli, F. Follath, D. Hack, R. Zaker, and et al. Prognostic impact of systemic inflammatory diseases in elderly patients with congestive heart failure QJM 107 2014 131 138
55. W. Chen, and N.G. Frangogiannis Fibroblasts in post-infarction inflammation and cardiac repair Biochim Biophys Acta 1833 2013 945 953
56. S. Toldo, H. Kannan, R. Bussani, M. Anzini, C. Sonnino, G. Sinagra, and et al. Formation of the inflammasome in acute myocarditis Int J Cardiol 171 2014 e119 e121
57. J. Haas, K.S. Frese, Y.J. Park, A. Keller, B. Vogel, A.M. Lindroth, and et al. Alterations in cardiac DNA methylation in human dilated cardiomyopathy EMBO Mol Med 5 2013 413 429
58. R. Kaneda, S. Takada, Y. Yamashita, Y.L. Choi, M. Nonaka-Sarukawa, M. Soda, and et al. Genome-wide histone methylation profile for heart failure Genes Cells 14 2009 69 77
59. C.A. Koczor, E.K. Lee, R.A. Torres, A. Boyd, J.D. Vega, K. Uppal, and et al. Detection of differentially methylated gene promoters in failing and nonfailing human left ventricle myocardium using computation analysis Physiol Genomics 45 2013 597 605
60. M. Asrih, and S. Steffens Emerging role of epigenetics and miRNA in diabetic cardiomyopathy Cardiovasc Pathol 22 2013 117 125
61. M. Movassagh, M.K. Choy, M. Goddard, M.R. Bennett, T.A. Down, and R.S. Foo Differential DNA methylation correlates with differential expression of angiogenic factors in human heart failure PLoS One 5 2010 e8564
62. R.L. Montgomery, C.A. Davis, M.J. Potthoff, M. Haberland, J. Fielitz, X. Qi, and et al. Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility Genes Dev 21 2007 1790 1802
63. T. Angrisano, G.G. Schiattarella, S. Keller, G. Pironti, E. Florio, F. Magliulo, and et al. Epigenetic switch at atp2a2 and myh7 gene promoters in pressure overload-induced heart failure PLoS One 9 2014 e106024
64. B. Duygu, E.M. Poels, and P.A. da Costa Martins Genetics and epigenetics of arrhythmia and heart failure Front Genet 4 2013 219
65. K. Pandya, and O. Smithies Beta-MyHC and cardiac hypertrophy: size does matter Circ Res 109 2011 609 610
66. G. Majumdar, I.M. Johnson, S. Kale, and R. Raghow Epigenetic regulation of cardiac muscle-specific genes in H9c2 cells by Interleukin-18 and histone deacetylase inhibitor m-carboxycinnamic acid bis-hydroxamide Mol Cell Biochem 312 2008 47 60
67. C. Marchetti, J. Chojnacki, S. Toldo, E. Mezzaroma, N. Tranchida, S.W. Rose, and et al. A novel pharmacologic inhibitor of the NLRP3 inflammasome limits myocardial injury after ischemia-reperfusion in the mouse J Cardiovasc Pharmacol 63 2014 316 322
68. S. Toldo, E. Mezzaroma, L. O'Brien, C. Marchetti, I.M. Seropian, N.F. Voelkel, and et al. Interleukin-18 mediates interleukin-1-induced cardiac dysfunction Am J Phys 306 2014 H1025 H1031
69. L.C. O'Brien, E. Mezzaroma, B.W. Van Tassell, C. Marchetti, S. Carbone, A. Abbate, and et al. Interleukin-18 as a therapeutic target in acute myocardial infarction and heart failure Mol Med 20 2014 221 229
70. C.J. Fisher Jr., J.M. Agosti, S.M. Opal, S.F. Lowry, R.A. Balk, J.C. Sadoff, and et al. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group N Engl J Med 334 1996 1697 1702
71. C.J. Fisher Jr., G.J. Slotman, S.M. Opal, J.P. Pribble, R.C. Bone, G. Emmanuel, and et al. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial Crit Care Med 22 1994 12 21
72. P.M. Ridker, T. Thuren, A. Zalewski, and P. Libby Interleukin-1beta inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) Am Heart J 162 2011 597 605
73. P.M. Ridker, C.P. Howard, V. Walter, B. Everett, P. Libby, J. Hensen, and et al. Effects of interleukin-1beta inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial Circulation 126 2012 2739 2748